BIO Stock Analysis: Buy, Sell, or Hold?
BIO - Bio-Rad Laboratories, Inc.Class A
$371.19
2.44 (0.66%)
â˛
5d:
-4.31%
30d:
+2.52%
90d:
+26.93%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When BIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BIO is fairly priced but lacks strong directional signals. At 7.8% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BIO is fairly priced but lacks strong directional signals. At 7.8% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$317.66
Based on 4.9% avg growth
INTRINSIC VALUE TODAY
$197.24
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIO is currently trading at $371.19, which is considered fair relative to its 30-day fair value range of $351.50 to $386.05. From a valuation perspective, the stock is trading at a premium (Forward PE: 36.8) compared to its historical average (29.4). At these levels, the market is pricing in 7.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BIO is in a strong uptrend. The price is currently testing key support at $368.56. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BIO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $329.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BIO is in a strong uptrend. The price is currently testing key support at $368.56. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BIO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $329.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$351.50 -
$386.05
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.2%
Protect Your Profits
Holding BIO? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 10.8% above Wall St target ($329.00)
- NEUTRAL: Trading at premium valuation - market expects 7.8% growth which is achievable
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$351.50 -
$386.05
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$14.01
(3.8%)
Support & Resistance Levels
Support Level
$368.56
Resistance Level
$394.29
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
36.77
Wall Street Target
$329.00
(-10.8%)
Revenue Growth (YoY)
-0.1%
Earnings Growth (YoY)
18.7%
Profit Margin
8.6%
Valuation Premium vs History
+7.8% premium
PE vs Historical
36.8 vs 29.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.8%
(market-implied from PE analysis)
1-Year Target
$397.51
(+8%)
2-Year Target
$428.52
(+16%)
3-Year Target
$461.94
(+25%)
3-Yr Target (if PE normalizes)
(PE: 37â29)
PE COMPRESSION
$369.33
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 36.8, Growth: 5.7%)
$436.04
(+18%)
Base:
(SPY PE: 20.2, Growth: 5.7%)
$239.17
(-35%)
Bear:
(PE: 17.1, Growth: 5.7%)
$203.30
(-45%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (46x PE), but valuation improves significantly next year (37x PE) as earnings recover.
Trailing PE: 45.92 | Current EPS (TTM): $8.21
Bull Case
$506.49
(+37%)
Analyst growth 22.1%, PE expands to 50.5
Base Case
$460.45
(+25%)
Market implied 22.1%, PE stable at 45.9
Bear Case
$256.34
(-31%)
Severe decline -20.0%, PE contracts to 39.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 11, 2026 2:53 PM ET
Data refreshes hourly during market hours. Next update: 3:53 PM
Data refreshes hourly during market hours. Next update: 3:53 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 40 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 44 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 41 HOLD |
Advanced BIO Option Strategies
Professional options setups generated by AI based on today's BIO price and gamma walls.
